Clinical trial · Interventional
R-CHOP + GM-CSF for Previously Untreated LCL in Elderly
Phase II Trial of Rituximab-CHOP (R-CHOP) Plus GM-CSF for Previously Untreated Diffuse Large Cell Lymphoma in the Elderly
NCT00582725CI-TRIAL-00042277completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients will receive 6 to 8 cycles of R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, and prednisone), with GM-CSF.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Large B-Cell, Diffuse | Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| R-CHOP+GM-CSF | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- R-CHOP + GM-CSF
- description
- R-CHOP therapy (6-8 cycles) with GM-CSF
- interventionNames
- Drug: R-CHOP+GM-CSF
Primary outcomes (1)
- measure
- Response Rate to Therapy
- timeFrame
- Dec 2005 approx
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed, CD20+ B cell diffuse large cell lymphoma, with measurable or evaluable disease * Having no prior chemotherapy, immunotherapy or radiotherapy except for one cycle of CHOP or R-CHOP. Exclusion Criteria: * Pregnant * Hepatitis B Surface Antigen positive * Have known CNS disease or HIV infection * Have NY Classification III or IV disease.
References
Publications (1)
- RESULTKahl BS, Bailey HH, Smith EP, Turman N, Smith J, Werndli J, Williams EC, Longo WL, Kim KM, McGovern J, Jumonville A. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study. Cancer Invest. 2005;23(1):13-8. PMID 15779863